KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-cash Items (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Non-cash Items for 15 consecutive years, with $949000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-cash Items rose 1877.08% year-over-year to $949000.0, compared with a TTM value of $2.0 million through Sep 2025, up 4114.58%, and an annual FY2024 reading of $57000.0, down 21.92% over the prior year.
  • Non-cash Items was $949000.0 for Q3 2025 at TherapeuticsMD, up from -$164000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $32.3 million in Q3 2022 and bottomed at -$6.4 million in Q1 2023.
  • Average Non-cash Items over 5 years is $3.6 million, with a median of $155000.0 recorded in 2022.
  • The sharpest move saw Non-cash Items tumbled 2011276.47% in 2023, then surged 1877.08% in 2025.
  • Year by year, Non-cash Items stood at $336000.0 in 2021, then plummeted by 99.95% to $170.0 in 2022, then crashed by 2011276.47% to -$3.4 million in 2023, then skyrocketed by 97.16% to -$97000.0 in 2024, then skyrocketed by 1078.35% to $949000.0 in 2025.
  • Business Quant data shows Non-cash Items for TXMD at $949000.0 in Q3 2025, -$164000.0 in Q2 2025, and $1.3 million in Q1 2025.